NANO SOMA Inhibits SARS-COV-2
NANO SOMA Inhibits SARS-COV-2
NANO SOMA has been shown to inhibit SARS-COV-2 viral entry by blocking TMPRSS2 and ACE2 receptor in vitro and has been demonstrated to protect SARS-COV-2 positive patients in 3 to 5 days.
Metadichol® (NANO SOMA), a nano lipid formulation of long chain alcohols, has been shown in vitro studies to protect against SARS-COV-2 and it does so by blocking the cell entry points for SARS-COV-2. The receptor ACE2 is used by the virus for entry and the serine protease TMPRSS2 for S protein priming. It inhibits both ACE2 and TMPRSS2. An assay against the virus using CACO2 cells showed that it had an EC90 of 0.16 µg/ml, which means it effectively eliminates the virus at a very low concentration.
Metadichol® inhibits TMPRSS2 (EC50 of 96 ng/ml). It is 270 times more potent than another well-known inhibitor Camostat mesylate, which has EC50 of (26000 ng/ml). Metadichol is also a moderate inhibitor of ACE2 with an EC50 of 31 µg/ml. Moderate inhibition of ACE2 allows it to perform its key functions in the body, yet fend off SARS-COV-2 entry to the cell. ACE2 lowers blood pressure, regulates intestinal neutral amino acid transport. ACE2 expression and function is increasingly recognized as a potential therapeutic strategy in hypertension and cardiovascular disease, diabetes, lung injury, and fibrotic disorders.
Metadichol, by binding to the Vitamin D receptor (VDR), acts on proteases like Furin and Adam-17, which activate the S-protein spikes for viral spread and pathogenesis in the infected hosts. In Malaria, CD147, also known as Basigin, is used by parasites to gain entry into the cell. Recent publications suggest that it also can be used as a point of entry by the SARS-COV-2 virus. Our previous work (US patent 9,006,292) showed that Metadichol is also potent against Malarial parasites and, by association, CD147. All these results and others are documented in our recent publication available at (https://www.researchsquare.com/article/rs-34021/v5)
A pilot study (outside the USA) on five SARS-COV-2 patients with minor indications showed the absence of a virus after 2-4 days of Metadichol @ 20 mg per day. To validate this further, we have initiated a study in collaboration with government agencies. The initial study of 30 patients showed 75% of the patients cleared of the SARS-COV-2 virus after 4 days of treatment – see http://nanorxeurope.com/Documents/India-hospital-letter.pdf
Can NANO SOMA protect me against SARS-COV-2?
As with perhaps all such infections, those most at risk from SARS-COV-2 are those with weakened immune systems. NANO SOMA substitutes for Vitamin D and also triggers the body to produce its own Vitamin C, an ability we lost 40M years ago. Both Vitamin C and Vitamin D play a key role in immunity. So, in these and other ways, NANO SOMA acts to strengthen your immune system, helping to protect you from all types of infection, including SARS-COV-2.